Sai Life Sciences Limited has completed the allotment of 2,44,281 fully paid-up equity shares under its employee stock option plans on 23 April 2026. The Board of Directors approved the allotment of shares upon exercise of options granted under the company's ESOP 2008 and MESOP 2018 schemes.

Share Allotment Details

The allotment was executed under two separate employee stock option plans with different pricing structures:

All shares carry a par value of Re.1 per share and have been issued in dematerialized form with distinctive numbers ranging from 211779235 to 212023515. The shares are identical in all respects to the existing equity shares of the company.

Financial Impact

The exercise of these stock options generated INR 3,38,38,171.30 for the company. This amount represents the total consideration received from employees who exercised their vested options under both schemes. The funds raised through this allotment will contribute to the company's working capital requirements.

Updated Share Capital Structure

Following this allotment, the company's capital structure has been updated as follows:

ESOP Scheme Framework

Both ESOP plans are designed to attract, retain and reward employees while contributing to the company's growth. The schemes feature a maximum vesting period of 5 years with multiple vesting options. The exercise period extends until the employee remains in service with the company, providing flexibility for option holders to exercise their rights based on market conditions and personal financial planning.

The company has filed the necessary regulatory disclosures with BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring full compliance with listing requirements.

Sai Life Sciences Limited has fulfilled its regulatory obligations by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed this compliance document with both BSE Limited and National Stock Exchange of India Limited on April 8, 2026.

Regulatory Compliance Details

The certificate submission represents a routine quarterly compliance requirement under SEBI regulations. KFin Technologies Limited, serving as the company's Registrar and Share Transfer Agent, issued the certificates dated April 2, 2026. These documents confirm that all necessary details regarding securities transactions have been properly reported to regulatory authorities.

Certificate Scope and Purpose

The certificates address both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) requirements. KFin Technologies Limited, through Deputy Vice President Ganesh Chandra Patro, certified that details of securities dematerialized and rematerialized during the quarter have been furnished to all stock exchanges where Sai Life Sciences shares are listed.

Stock Exchange Filings

Sai Life Sciences maintains listings on major Indian stock exchanges with specific identifiers for trading purposes. The company filed identical certificates with both depositories to ensure comprehensive compliance coverage. Company Secretary and Compliance Officer Runa Karan signed the submission documents, confirming the company's adherence to regulatory timelines.

This quarterly submission demonstrates Sai Life Sciences' commitment to maintaining transparent regulatory compliance and ensuring proper documentation of all securities transactions through authorized depositories.